Teva Pharmaceuticals
TEVA
Market cap $20.4B

18.01 USD

-0.17

0.94%

Updated Oct 22, 10:48 AM EDT

1 day

-0.94%

5 days

-0.99%

1 month

1.64%

3 months

6.07%

6 months

39.83%

Year to date

68.79%

1 year

120.17%

5 years

124.28%

About: Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Employees: 37,851

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

364% more call options, than puts

Call options by funds: $577M | Put options by funds: $124M

156% more first-time investments, than exits

New positions opened: 87 | Existing positions closed: 34

23% more repeat investments, than reductions

Existing positions increased: 187 | Existing positions reduced: 152

21% more capital invested

Capital invested by funds: $8.15B [Q1] → $9.89B (+$1.75B) [Q2]

11% more funds holding

Funds holding: 471 [Q1] → 524 (+53) [Q2]

4% more funds holding in top 10

Funds holding in top 10: 24 [Q1] → 25 (+1) [Q2]

2.22% more ownership

Funds ownership: 51.54% [Q1] → 53.77% (+2.22%) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$18

0%

upside

Avg. target

$22

22%

upside

High target

$26

44%

upside

3 analyst ratings

2 positive

67%

1 neutral

33%

0 negative

0%

JP Morgan Chris Schott 33% 1-year accuracy 3 / 9 met price target	0%downside $18	Neutral Maintained	21 Oct 2024
UBS Ashwani Verma 53% 1-year accuracy 9 / 17 met price target	44%upside $26	Buy Maintained	3 Sept 2024
Barclays Balaji Prasad 38% 1-year accuracy 12 / 32 met price target	22%upside $22	Overweight Maintained	1 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 13 articles about TEVA published over the past 30 days

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

REYKJAVIK, Iceland & PARSIPPANY, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) in a new presentation, 130 mg/26 mL (5 mg/mL) solution in a single-dose vial for intravenous infusion. This approval paves the way for SELARSDI to further align its label with the indications of the reference product Stelara® (ustekinumab) in the U.S. at launch, which is expected in the first quarter of 2025.

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

3 Attractive Biotechs With Recent Positives

The small cap biotech sector is trading close to the same levels that it was five years ago. Straight equity holdings have threaded water in this space over the past half decade. However, given the lucrative option premiums available against many names in this area, a covered call strategy has worked quite successfully for my portfolio on a consistent basis.

3 Attractive Biotechs With Recent Positives

Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug

On Thursday, Amicus Therapeutics FOLD announced that it has entered into a License Agreement with Teva Pharmaceuticals Inc. TEVA.

Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug

Teva agrees to pay $450m to resolve kickback allegations, US Justice Dept says

New Jersey-based drugmaker Teva has agreed to pay $450 million to resolve allegations that it violated an anti-kickback statute and the False Claims Act, the U.S. Justice department said in a statement on Thursday.

Teva agrees to pay $450m to resolve kickback allegations, US Justice Dept says

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

TEL AVIV, Israel, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted, and the European Medicines Agency (EMA) has validated, applications for TVB-009P, a biosimilar candidate to Prolia® (denosumab).1

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

Zacks Investment Research

Is Teva Pharmaceutical Industries (TEVA) Stock Outpacing Its Medical Peers This Year?

Here is how Teva Pharmaceutical Industries Ltd. (TEVA) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.

Is Teva Pharmaceutical Industries (TEVA) Stock Outpacing Its Medical Peers This Year?

Zacks Investment Research

Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

TEL AVIV, ISRAEL and MADRID, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced a new global licensing agreement for the development of an anti PD-1 oncology biosimilar candidate. This marks the second agreement between the two companies, reinforcing the solid foundation of the collaborative efforts that commenced in April 2024.

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.

PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and only generic version of Sandostatin®1 LAR Depot, in the United States.

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024

TEL AVIV, Israel, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its financial results for the third quarter of 2024 on Wednesday, November 6, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024

See News Rankings

Charts implemented using Lightweight Charts™